1. ALLA AKTIER
  2. NYHETER
  3. INITIATOR PHARMA

Initiator Pharma

Nyheter Initiator Pharma Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Last day of trading in BTA in Initiator Pharma

MARKN.

Initiator Pharma A/S (“Initiator Pharma” or “the Company”) rights issue has now been registered with the Danish Companies Registration Office. The Company hereby announces that the last day of trading in paid subscribed shares (Sw. BTA) will be on 21 July 2022 and stop day will be on 25 July 2022.

In June 2022, Initiator Pharma conducted a rights issue, which provided the Company with approximately SEK 41 million before transaction related costs. The rights issue has now been registered with the Danish Companies Registration Office and the last day of trading in BTA will be on 21 July 2022 and stop day will be on 25 July 2022. The shares are estimated to be delivered to each shareholder’s account on 27 July 2022.

Through the rights issue, Initiator Pharma’s share capital have increased by DKK 573,659.73, from DKK 4,924,338.405 to DKK 5,497,998.14. The total number of shares have increased by 5,463,426, from 46,898,461 to 52,361,887.

For additional information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: ceo@initiatorpharma.com

About Initiator Pharma

Initiator Pharma A/S is a Danish clinical stage life science company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of three clinical programs - the drug candidates IP2018 and IPED2015 for treatment of erectile dysfunction of psychogenic and organic origin, respectively, and the orphan drug candidate IPTN2021 developed for Trigeminal Neuralgia, a severe neuropathic pain condition. 
 
Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye AB, with email address certifiedadviser@redeye.se and phone number +46 8 121 576 90, is the company’s Certified Adviser. For more information, please visit www.initiatorpharma.com.

Attachments

Last day of trading in BTA in Initiator Pharma

Datum 2022-07-18, kl 08:30
Källa MFN
Bifogade filer
Last day of trading in BTA in Initiator Pharma